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Abstract
Aims Vascular perfusion may be impaired
in primary open-angle glaucoma (POAG);
thus, we evaluated a panel of markers in
vascular tone-regulating genes in relation
to POAG.
Methods We used Illumina 660W-Quad
array genotype data and pooled P-values
from 3108 POAG cases and 3430 controls
from the combined National Eye Institute
Glaucoma Human Genetics Collaboration
consortium and Glaucoma Genes and
Environment studies. Using information from
previous literature and Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathways,
we compiled single-nucleotide polymorphisms
(SNPs) in 186 vascular tone-regulating
genes. We used the ‘Pathway Analysis by
Randomization Incorporating Structure’
analysis software, which performed 1000
permutations to compare the overall pathway
and selected genes with comparable randomly
generated pathways and genes in their
association with POAG.
Results The vascular tone pathway was not
associated with POAG overall or POAG
subtypes, defined by the type of visual field
loss (early paracentral loss (n¼ 224 cases) or
only peripheral loss (n¼ 993 cases))
(permuted PZ0.20). In gene-based analyses,
eight were associated with POAG overall at
permuted Po0.001: PRKAA1, CAV1, ITPR3,
EDNRB, GNB2, DNM2, HFE, and MYL9.
Notably, six of these eight (the first six listed)
code for factors involved in the endothelial
nitric oxide synthase activity, and three of
these six (CAV1, ITPR3, and EDNRB) were
also associated with early paracentral loss at
Po0.001, whereas none of the six genes
reached Po0.001 for peripheral loss only.
Discussion Although the assembled
vascular tone SNP set was not associated
with POAG, genes that code for local factors
involved in setting vascular tone were
associated with POAG.
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Introduction
Primary open-angle glaucoma (POAG), a
leading cause of blindness, is characterized by
visual field (VF) loss due to retinal ganglion cell
death.1 It is believed that there are multifactorial
contributors to POAG aetiology in addition to
elevated intraocular pressure (IOP), an
established risk factor. One major contributor
may be regulation of vascular tone.2–6 For
example, glaucoma patients have impaired
blood flow and vascular autoregulation in eye
tissues,7–11 and exhibit impaired flow- 12 or
acetylcholine-mediated13 vasodilation in the
brachial artery and reduced blood flow in finger
nailfold capillaries,14 suggesting systemic
vascular abnormalities. Of note, POAG patients
with initial paracentral VF loss are particularly
more likely to have systemic vascular risk
factors, such as hypotension and migraines.15–17
Many studies support the role of vascular
factors in glaucoma. Large epidemiologic
studies have observed adverse associations with
low ocular perfusion pressure18 or low systemic
blood pressure,19 and open-angle glaucoma
frequency or risk.20,21 In addition, the Early
Manifest Glaucoma Trial22 identified predictors
of POAG disease progression that included
lower systolic blood and perfusion pressure.
Recent large POAG genome-wide association
studies (GWAS) have identified significant
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associations for single-nucleotide polymorphism (SNP) in
the genomic region containing CAV1,23–25 which codes for
caveolins that are involved in vascular regulation, thereby
supporting the role of vascular dysregulation in POAG.
Because biologic pathway analyses (where SNP sets from
functionally related genes are collectively evaluated in
relation to a disease of interest) can enhance the power to
discover aetiologically relevant pathways and networks,
we tested the hypothesis of whether a collection of SNPs
in genes functionally involved in vascular tone regulation
and identified as significant hits in GWAS of blood
pressure are possibly associated with POAG.
In this study, we used high-throughput genotyping SNP
data from the Glaucoma Genes and Environment
(GLAUGEN) study and the National Eye Institute
Glaucoma Human Genetics Collaboration (NEIGHBOR)
consortium to assemble a vascular tone SNP panel (8671
SNPs in 186 genes) and used the Pathway Analysis by
Randomization Incorporating Structure (PARIS) analysis
software package (freeware developed by Dr Marilyn
Ritchie, Pennsylvania State University, University Park, State
College, PA, USA)26 for pathway analysis. In exploratory
analyses, we assessed whether collections of SNPs within
genes that comprise the pathway are associated with POAG.
Material and methods
Study population
We used meta-analysed GWAS data from two studies in the
United States: GLAUGEN and NEIGHBOR. The
GLAUGEN study included nested case–control samples
(976 POAG cases and 1140 controls) from the population-
based cohorts of the Nurses’ Health Study (NHS) and
Health Professionals Follow-up Study (HPFS), as well as a
clinical case–control sample from the Massachusetts Eye
and Ear (MEE). The data from GLAUGEN have been
evaluated in investigations of genetic factors and
gene–environment interactions in POAG.27,28 A recent
publication describes the criteria for inclusion and exclusion
for GLAUGEN,23 and the details are also available at dbGaP,
accession number phs000308.v1.p1. The NEIGHBOR study
included 2132 POAG cases and 2290 controls from 12
institutions and also provided data for genetic investigations
of central corneal thickness,29,30 IOP,31 and POAG.28 The
descriptive information about the design, inclusion/
exclusion criteria, study sites, and collected data in the
NEIGHBOR study was recently published.32
POAG case and control definitions
All POAG cases were required to have at least one eye
with either (1) a cup-to-disc ratio (CDR)40.7 and VF loss
consistent with glaucoma on one reliable VF test or
(2) the same VF loss evident on at least two reliable VF
tests (reliability of a VF test was defined as fixation loss
r33%, false positives r20%, and false negatives r20%).
The reproducible VF defect(s) evident on reliable tests
were compatible with glaucomatous patterns of nerve
fibre layer loss. The type of VF test was not specified,
although most cases had threshold VF tests on the
Humphrey perimeter. On the basis of slit-lamp
biomicroscopy, none of the cases had evidence of
exfoliation syndrome, pigment dispersion syndrome, or
other glaucoma diagnoses that could produce
secondary elevation of IOP. In addition, all cases had
documentation of open iridocorneal filtration angles in
both eyes. POAG cases were included at the full
spectrum of IOP at diagnosis, including both normal
tension glaucoma cases with IOP r21 mm Hg and high
tension glaucoma cases with IOP 421 mm Hg. Controls
identified in clinical settings underwent eye exams that
showed IOP r21 mm Hg and CDR r0.6 in both eyes.
For nested case–control study controls (from NHS and
HPFS), controls reported having had an eye exam at the
same time period as the index cases and did not report
a glaucoma diagnosis.
Each case was categorized into POAG subtypes
defined by type of VF loss: early paracentral VF loss
(with or without peripheral VF loss) or peripheral VF
loss only (without any paracentral loss). The earliest VF
report for each case was systematically reviewed such
that pattern deviation plots were subdivided into
paracentral, Bjerrum, nasal step, and temporal wedge
zones above and below the horizontal meridian
(Figure 1). Two reviewers who were masked to genotype
status assessed VFs, and any differences in VF loss-type
designation were adjudicated for establishing a
consensus designation. The presence of clusters of three
or more contiguous points with reduced retinal
sensitivity of one-half log unit ( 5 dB) relative to age-
matched controls were considered to show VF loss; the
location of such loss was determined for each of the four
regions. Cases were defined as having POAG with ‘early
paracentral loss’ in the two studies differently: in the
GLAUGEN data set, where cases were incident cases
from population-based studies with early VF loss, cases
had VF loss that occurred in the paracentral zone with or
without loss in other peripheral zones, whereas in the
NEIGHBOR data set, where cases were prevalent cases
from tertiary clinic-based case–control studies with
advanced disease, to capture ‘early paracentral loss’,
cases had to have VF loss that occurred in the paracentral
zone only without any loss in other peripheral zones.
Cases were defined as having POAG with ‘peripheral
loss only’ in both GLAUGEN and NEIGHBOR data sets
if cases had VF loss in any of the other peripheral zones
without loss in the paracentral zone.
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Genotyping and analyses of genotype associations
Genotyping with the Illumina 660W-Quad array (Illumina,
San Diego, CA, USA) was conducted at the Broad Institute
(Cambridge, MA, USA) for GLAUGEN and at the Center
for Inherited Disease Research (Baltimore, MD, USA) for
NEIGHBOR. The details of the methods used for DNA
collection, extraction and plating, the algorithm for calling
genotypes, the SNP quality control (QC) filters used, and
the preliminary analyses undertaken to discover
independent predictors of genotype calling rates adjusted
for in this paper have been provided in previous
publications for both GLAUGEN and NEIGHBOR.23,28 For
analyses of genotype associations with POAG, PLINK
v.1.0733 was used with SNPs that passed the QC filters
(484 419 SNPs in GLAUGEN and 521 683 SNPs in
NEIGHBOR). Analyses were conducted among self-
reported Caucasians and were adjusted for population
structure, age, gender, and study site in both study groups,
and analyses in GLAUGEN were additionally adjusted for
the three different DNA extraction methods used and
DNA source (blood or cheek cell sample).23,28 Using the
METAL software,34 the GLAUGEN and NEIGHBOR data
were meta-analysed, and pooled P-values were obtained
for the 480 335 overlapping SNPs in the combined data set.
Defining the vascular tone pathway and analysis of the
whole pathway and of specific genes
In this paper, we used the P-values for the association
with POAG for 8671 unique SNPs in the vascular tone
pathway for the analysis that is discussed below. We
generated a custom list comprising the vascular tone
pathway (see Figure 2) of 8671 SNPs in 186 genes
(Supplementary Table 1) across all autosomes. We used
the Kyoto Encyclopedia of Genes and Genomes
(KEGG)35 online database and other academic
sources,36,37 as well as a recent review38 of the GWAS
findings for blood pressure.
We uploaded the meta-analysed P-values of the selected
SNPs within these genes residing in the EMSEMBL
genomic interval±a 50 kB window to PARIS software
from the combined GLAUGEN–NEIGHBOR data set. The
analytic approach with the PARIS software has been
described.26 Briefly, for the assembled pathway, PARIS
first determined important parameters such as the
number of linkage disequilibrium (LD) blocks, the
number of SNPs per block, and the number of SNPs not in
any LD block. The vascular tone pathway contained 1405
complex features (LD blocks with two or more SNPs) and
1779 simple features (single SNPs not in any LD block).
Then, PARIS conducts a comparison of the overall
association of the vascular tone pathway with POAG to
the associations of 1000 randomly generated pathways
with genetic architectures similar to the vascular tone
pathway with POAG; in this comparison, PARIS provides
a permuted P-value, which helps determine whether the
assembly of SNPs in the pathway of interest as a whole
may be significantly associated with POAG. We chose to
produce 1000 random pathways, as generating another
order of magnitude more pathways with similar genetic
architecture would have been prohibitive computa-
tionally. To illustrate the methodology of how the random
SNP sets are used to assess statistical significance for SNP
sets of interest, we, as described previously,39 evaluated
an oestrogen pathway among women using the same data
set. The results indicated 31 significant features in this
pathway, and PARIS generated a significant permuted
P-value¼ 0.007. This indicated that only 7 of 1000 random
pathways with a genetic architecture similar to the
oestrogen pathway had more features that were
statistically significant at Po0.05 level in relation to POAG
than the oestrogen pathway (i.e., 431 significant features
with Po0.05). This overall significant permuted P-value
of 0.007 indicated that the assembly of SNPs in the
oestrogen pathway was significantly associated with
POAG, supporting the role of oestrogen in the aetiology
of POAG.39 We used a similar approach in this study to
evaluate the vascular pathway in relation to POAG.
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Figure 1 Paracentral and peripheral VF loss definitions.
Representative VF pattern deviation plot used for defining the
type of VF loss. The box with a dashed line indicates the
superior paracentral region. The boxes with solid lines represent
the superior nasal step and temporal wedge regions, as well as
the inferior Bjerrum region, which are all peripheral regions. For
a case to be defined as having early paracentral loss, VF loss in
the superior or inferior paracentral zones had to be present; in
the GLAUGEN data set, VF loss in other peripheral zones were
allowed, whereas in the NEIGHBOR data set, VF loss in other
peripheral zones were not allowed. For a case to be defined as
having peripheral loss, VF loss in the superior and/or inferior
nasal step, temporal wedge, or Bjerrum regions had to be
present, with no loss in the paracentral regions.
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region is considered to be more strongly associated with
vascular abnormalities,15–17 in addition to overall POAG,
we evaluated subtypes of POAG defined by the type of
VF loss separately (POAG with early VF loss in the
paracentral region and POAG with VF loss in the peripheral
region only), to investigate differences in association.
In subsequent analyses, to determine whether some
genes or SNPs in the vascular tone pathway were
significantly associated with POAG, we used the
‘-I’ (Investigate) option within PARIS, which reports the
P-values of genes and SNPs within the pathway. In an
approach that was similar to the overall pathway
Figure 2 Vascular tone pathway. This pathway was custom-generated by using sources from the Kyoto Encyclopedia of Genes and
Genomes35 online database and other academic sources,36,37 as well as a recent review38 of the GWAS findings for blood pressure.
Proteins coded by genes included in the analysis are in grey. Substrates and reaction products are in green. Overall, the vascular tone
pathway was not significantly associated with POAG permuted P¼ 0.87. In exploratory analyses, of the eight proteins of genes with
permuted P-values o0.001, seven are indicated with red squares, with the remaining being the HFE gene, which was included in the
analysis as part of genes identified from a review38 of known blood pressure SNPs.
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approach, we assessed the association with POAG of the
aggregate SNPs within specific genes in the vascular tone
pathway to gain insight into which aspects of the
pathway may be aetiologically important. Because we
evaluated 186 genes in this pathway in relation to three
outcomes, there was the potential for significant findings
arising owing to chance because of multiple testing. In
the PARIS methodology, the genome is permuted rather
than applying a Bonferroni correction for multiple testing
(to avoid the risk of penalizing larger genes as might
happen with Bonferroni correction).26 To minimize
false-positive findings, we focused on genes that showed
permuted Po0.001 (which represented the lowest
possible permuted P-value, as such P-values are based
on counts of 1000 random pathways per genes; that is, a
count of 1 randomly generated pathway that shows more
significant features than the vascular tone pathway out of
1000 random pathways yields a permuted P¼ 0.001, and
0 out of 1000 random pathways leads to a permuted
P-value of Po0.001).
We certify that all applicable institutional and
governmental regulations concerning the ethical use of
data from human volunteers were followed during this
research, and the Institutional Review Boards of the
participating institutions of GLAUGEN and NEIGHBOR
approved this study.
Results
A total of 3430 controls (2290 from NEIGHBOR and 1140
from GLAUGEN) and 3108 cases (2132 from NEIGHBOR
and 976 from GLAUGEN) and were analysed in the
study (Table 1). Of these 3108 cases, 224 had POAG with
early paracentral VF loss, whereas 993 had POAG with
peripheral VF loss only.
The vascular tone pathway was not significantly
associated with POAG overall (permuted P¼ 0.87); the
results were similarly null (permuted PZ0.81) in men
and women analysed separately (data not shown). In
addition, the vascular tone pathway was not associated
with POAG subtypes defined by VF loss: the permuted
P-value in relation to early paracentral VF loss was 0.20,
whereas the corresponding P-value for peripheral VF
loss only was 0.39.
In gene-based analyses, eight genes were associated
with overall POAG at permuted P-value o0.001
(Table 2), and the red-boxed items in Figure 2 are the
corresponding proteins for seven of the eight (HFE is
not included; HFE was a gene with loci that were
significantly associated with blood pressure in a recent
review38 of the GWAS studies of blood pressure).
Of these eight genes, six were those coding for proteins/
enzymes that interact with endothelial nitric oxide
synthase (eNOS): PRKAA1, CAV1, ITPR3, EDNRB, GNB2,
and DNM2. Supplementary Table 2 shows the
association between individual SNPs within these eight
genes (residing in the EMSEMBL genomic interval±a
50 kB window) and POAG.
In addition, three of these (CAV1, ITPR3, and EDNRB),
along with HFE, were also associated with the subtype of
POAG with early paracentral VF loss with the permuted
P-value of o0.001, and PRKAA1 showed borderline
significance with the permuted P-value of 0.05. In contrast,
none of these reached permuted P-value o0.001 for the
subtype of POAG with peripheral VF loss only. However,
as observed for POAG with early paracentral VF loss,
nominally significant permuted P-values were observed
for CAV1 (P-value¼ 0.004) and PRKAA1 (P-value¼ 0.05) in
relation to POAG with peripheral VF loss only.
For the subtype of POAG with early paracentral VF
loss, one other gene, ADCY7, which was not associated
with POAG overall, was found to be associated with this
subtype with permuted Po0.001 (data not shown).
Notably, ADCY7 codes for a protein that influences eNOS
activity. For the subtype of POAG with peripheral VF
loss only and not overall POAG or the subtype with early
paracentral VF loss (data not shown), there were eight
different genes that were associated only with this
subtype with permuted Po0.001: PRKAA2, PRKAB2,
GNB5, PIK3CG, WNK1, PRKCA, ADORA2A, and AGTR1.
Of note, four of these 8 (PRKAA2, PRKAB2, GNB5, and
PIK3CG) also coded for proteins that interact with eNOS.
Discussion
In this first study of the collective SNPs in genes involved
in the vascular tone pathway and POAG, we observed
that the assembled vascular tone pathway SNP panel
was not related to the main outcome of overall POAG
diagnosis or the subtypes of POAG with early VF loss in
the paracentral region or POAG with VF loss in the
Table 1 Pathway analysis results using data from the com-
bined GLAUGEN and NEIGHBOR: significance of the associa-
tion of the overall vascular tone pathway in relation to POAG,
POAG with early paracentral visual field loss, and POAG with




Cases Controls Cases Controls
POAG 3108 3430 65.7 67.7 0.87
POAG with early paracentral
visual field loss
224 3430 64.8 67.7 0.20
POAG with peripheral visual
field loss only
993 3430 64.8 67.7 0.39
Abbreviations: GLAUGEN, the Glaucoma Genes and Environment
study; NEIGHBOR, National Eye Institute Glaucoma Human Genetics
Collaboration; POAG, primary open-angle glaucoma.
a P-values are permuted P-values.
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peripheral region only. However, in gene-based analysis,
eight genes were associated with POAG with permuted
Po0.001, and of these eight genes, six coded for proteins
that interact with eNOS. In particular, three of these six
were also significantly related (permuted Po0.001) to the
POAG subtype that is characterized by early paracentral
VF loss. Thus, although this study did not find
associations with the vascular tone panel as a whole, it
generated further support for the more specific role of
eNOS-related activity in POAG.
Because a myriad of extrinsic (factors that originate
from outside the local tissue that affect the arterial blood
pressure) and intrinsic factors (local factors that regulate
local blood flow) affect vascular tone,3 the panel tested
included a comprehensive set of 186 genes (8671 unique
SNPs) based on the KEGG pathways and GWAS
significant associations for blood pressure based on a
recent review.38 The overall null association may have
been due to the inclusion of SNPs from gene-regulating
factors that may affect blood pressure or regulate
vascular tone systemically but are not relevant for blood
flow regulation, especially to the optic nerve head
(ONH). For example, hormones such as epinephrine,
vasopressin, and natriuretic peptides40–42 or neurogenic
factors43 are unlikely to affect the regulation of blood
flow to the retina and the ONH (e.g., blood vessels in the
retina and the ONH are not innervated),40 whereas
intrinsic factors such as vascular endothelial vasoactive
agents have an important role in influencing blood flow
autoregulation and vascular tone in the ONH.3,44,45
Of these agents, NO, generated constitutively by eNOS,
has a key role in maintaining the basal vasodilator tone in
ocular arteries.40,46–52 The major contribution of NO to
vascular tone in human ocular vasculature is
demonstrated by the observation that systemic
administration of an NOS inhibitor reduced blood flow
in the ONH53–55 and by the involvement of NO in the
POAG-related vascular conditions, such as hypertension,
hypotension, and vasospasms.56
Evidence of abnormal NO production in glaucoma is
also provided by genetic studies. Although genetic
studies have evaluated SNPs of factors related to the
renin–angiotensin system57–59 and the b-adrenoreceptors60,61
in relation to POAG, they have been small and
conflicting. However, relatively more consistent
associations are observed with genetic studies of
eNOS-related factors and POAG.62–67 Although not all
studies have found associations with variants in the
NOS3 gene that codes for eNOS,68,69 variants or
haplotypes of SNPs in NOS3 have been reported to
be associated with POAG overall,62,65 POAG with
migraines,66 POAG or high tension POAG among
women only,63,64 and familial POAG.67 Furthermore, the
CAV1/CAV2 gene region, which codes for caveolins that
control eNOS activity, contain variants associated with
POAG in one GWAS,24 and this finding was replicated in
another large candidate gene study.23 The caveolin/eNOS
interaction is critical to prevent inadequate NO
production under basal conditions and to the translation
of extracellular stimuli to intracellular NO signals.70
Consistent with this previous literature, it is suggestive
that six of the eight most significant associations in the
gene-based analyses were genes encoding proteins that
interact with eNOS; based on information from large
databases of gene expression in various human tissues,
all eight genes showed expression in human retinal
tissue.71,72 ITPR3 codes for inositol triphosphate receptor
(IP3R); when IP3 binds to IP3R, calcium levels increase,



















50 AMP-activated protein kinase AMPK PRKAA1c 5 0 2 o0.001 0.05 0.05
Inositol 1,4,5-trisphosphate receptor, type 3 IP3R ITPR3c 6 14 9 o0.001 o0.001 40.99
Hemochromatosis protein — HFE 6 0 2 o0.001 o0.001 0.07
Caveolin-1/caveolin 2 CAV1 CAV1c 7 2 6 o0.001 o0.001 0.004
G-protein subunit b-2 G beta GNB2c 7 0 2 o0.001 40.99 40.99
Endothelin receptor type B ETB EDNRBc 13 0 1 o0.001 o0.001 40.99
Dynamin II Dyn2 DNM2c 19 2 7 o0.001 0.06 40.99
Myosin regulatory light polypeptide 9 MLC MYL9 20 0 1 o0.001 40.99 40.99
Abbreviations: Chr, chromosome; GLAUGEN, the Glaucoma Genes and Environment study; LD, linkage disequilibrium; NEIGHBOR, National Eye
Institute Glaucoma Human Genetics Collaboration; POAG, primary open-angle glaucoma; SNP, single-nucleotide polymorphism.
a Simple features refer to single SNPs not in any LD block; complex features refer to LD blocks with two or more SNPs.
b P-values are permuted P-values.
c Genes for proteins that interact with endothelial nitric oxide synthase; see Figure 2.
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activating calmodulin, and causing dissociation of
caveolin from eNOS. The increased calcium levels
directly or indirectly via dynamin 2 (Dyn2), coded by
DNM2, activate eNOS. EDNRB codes for endothelin
receptor type B (ETB, which is particularly highly
expressed in retina71,72) and PRKAA1 codes for AMP
kinase (AMPK); both are additional activators of eNOS.
Finally, GNB2 codes for G-protein subunit-b (G beta) that
activates PI3K, which in turn activates Akt; Akt then
activates eNOS. A limitation of this study was that
variants in NOS3, which codes for eNOS, were not
significantly associated with POAG, although this could
be due to the low coverage (only two non-functional
SNPs rs7830 and rs3918188 were included) of the NOS3
SNPs on the Illumina 660W quad platform. This might
also be observed if NOS3 effects derive primarily from
multiple different rare variants rather than from effects of
the kinds of common variants used in this study.
Out of the eight genes showing significant association
with POAG, only MYL9, coding for myosin regulatory
light polypeptide 9 (MLC) and HFE, which codes for
hemochromatosis protein involved in iron metabolism,
are not directly involved in eNOS activation. Interestingly,
HFE was associated with both POAG overall and the
POAG subtype with early paracentral VF loss. Although
there are no previous reports of an association between
hemochromatosis and glaucoma, iron supplementation
has been linked to POAG;73 thus, the association between
POAG and iron levels or hemochromatosis warrants
further study.
Of the eight genes with Po0.001 associated with
POAG overall, three (CAV1, ITPR3, and EDNRB)
genes involved in eNOS activity were also associated
with the subtype of POAG with early paracentral VF
loss, even though we included only 224 such cases.
In addition, ADCY7, which codes for adenylate cyclase
that activates eNOS, was also significantly related to
this subtype. In contrast, none of the genes significantly
associated with POAG overall or the POAG subtype
with early paracentral VF loss were associated with
the POAG subtype with only peripheral VF loss.
This is consistent with previous findings showing
associations between the POAG subtype showing early
paracentral VF loss with systemic vascular
dysregulation.15,17
Among the limitations of this study, first, we lacked
replication of the gene-based analyses as there is
currently no other data set of comparable size for
replication. Thus, although suggestive, these gene-based
exploratory analyses, especially in relation to the subtype
of POAG with early paracentral VF loss, should be
interpreted with caution and replicated. Second, this
study was restricted to Caucasians and, therefore, the
generalizability of these results to other populations,
especially East Asian populations with generally lower
IOP,15,17,57 is limited.
In this large study to evaluate the collective influence
of genes coding for proteins influencing vascular tone,
we did not observe associations with POAG. However, in
gene-based analysis, we observed confirmatory results
supporting the role of the dysregulation of eNOS activity
in POAG aetiology.
Summary
What was known before
K Several lines of evidence suggest that vascular
autoregulation and perfusion may be impaired in POAG;
recently, large POAG GWAS have identified significant
associations for SNP in the genomic region containing
CAV1, which codes for caveolins that are involved in
vascular regulation, thereby supporting the role of
vascular dysregulation in POAG.
What this study adds
K Because biologic pathway analyses (where SNP sets from
functionally related genes are collectively evaluated in
relation to a disease of interest) can enhance the power to
discover aetiologically relevant pathways and networks,
we tested the hypothesis of whether a collection of SNPs
in genes functionally involved in vascular tone regulation
and identified as significant hits in GWAS of blood
pressure are possibly associated with POAG. This study
provides further support that specific genes that code for
local factors involved in setting vascular tone may be
associated with POAG.
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